Søren Cold

Medicin og biovidenskab

1. Breast Neoplasms 100%
2. Selenium 30%
3. Trastuzumab 26%
4. Neoplasm Metastasis 24%
5. Placebos 18%
6. N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide 16%
7. Adjuvant Chemotherapy 15%
8. Cyclophosphamide 15%
9. Disease-Free Survival 15%
10. Neoplasms 14%
11. Long Noncoding RNA 14%
12. Communication 13%
13. Denmark 13%
14. Drug Therapy 13%
15. Docetaxel 12%
16. Epirubicin 12%
17. Survival 12%
18. Randomized Controlled Trials 12%
19. Methotrexate 11%
20. Case-Control Studies 11%
21. Fluorouracil 10%
22. Yeasts 10%
23. Diphosphonates 10%
24. Tamoxifen 9%
25. Elderly 9%
26. Therapeutics 9%
27. Gene Expression Profiling 9%
28. Population 8%
29. Blood Proteins 8%
30. Mass Spectrometry 8%
31. General Practitioners 8%
32. 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzimidazol-5-yl)pyrimidin-2-yl)amine 8%
33. ribociclib 8%
34. Confidence Intervals 8%
35. Cohort Studies 7%
36. Hormones 7%
37. Pamidronate 7%
38. palbociclib 7%
39. Megestrol Acetate 6%
40. human ERBB2 protein 6%
41. Lymph Nodes 6%
42. Pregnancy-Associated Plasma Protein-A 6%
43. Insulin-Like Growth Factor Binding Protein 2 6%
44. Leukocytes 6%
45. Circulating MicroRNA 6%
46. Neoplasm Genes 6%
47. Levetiracetam 6%
48. Antisense RNA 5%
49. Capecitabine 5%
50. Everolimus 5%